1. Prognostic and Predictive Molecular Markers in Cholangiocarcinoma
   Sandra Pavicevic et al, 2022, Cancers CrossRef
2. SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models
   Elizabeth Gray et al, 2023, Journal for ImmunoTherapy of Cancer CrossRef
3. Comprehensive molecular profiling of the B7 family in gastrointestinal cancer
   Qijie Zhao et al, 2018, Cell Proliferation CrossRef
4. Prognostic impact of CD8+ T cell distribution and its association with the HLA class I expression in intrahepatic cholangiocarcinoma
   Yoh Asahi et al, 2020, Surgery Today CrossRef
5. Prognostic Role of Immune Checkpoint Regulators in Cholangiocarcinoma: A Pilot Study
   Lu Cao et al, 2021, Journal of Clinical Medicine CrossRef
6. Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers
   Guoying Zhou et al, 2022, British Journal of Cancer CrossRef
7. Crosstalk between the B7/CD28 and EGFR pathways: Mechanisms and therapeutic opportunities
   Xiaoxin Ren et al, 2022, Genes & Diseases CrossRef
8. New B7 Family Checkpoints in Human Cancers
   Ling Ni et al, 2017, Molecular Cancer Therapeutics CrossRef
9. Prognostic significance of B7-H4 expression in matched primary pancreatic cancer and liver metastases
   Yun Qian et al, 2016, Oncotarget CrossRef
10. Prognostic Value of B7H4 Expression in Patients with Solid Cancers: A Systematic Review and Meta-Analysis
    Miriam Dawidowicz et al, 2024, International Journal of Molecular Sciences CrossRef
11. Prognostic biomarkers for cholangiocarcinoma and their clinical implications
    Charupong Saengboonmee et al, 2018, Expert Review of Anticancer Therapy CrossRef
12. Clinicopathological and Prognostic Significance of Immunoscore and PD-L1 in Intrahepatic Cholangiocarcinoma
    Hong Wu et al, 2021, OncoTargets and Therapy CrossRef
13. A B7-H4–Targeting Antibody–Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression
    Sarah B. Gitto et al, 2024, Clinical Cancer Research CrossRef
14. Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody–Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305
    Krista Kinneer et al, 2023, Clinical Cancer Research CrossRef
15. B7-H4 is a prognostic biomarker for poor survival in patients with pancreatic cancer
    Lingwei Shen et al, 2017, Human Pathology CrossRef